Cisplatin DDP Resistant Subline of The A549 Lung Cancer Cells (A549/DDP)

A549/DDP is a cisplatin-resistant subline of the A549 human lung cancer cell line that has been developed through continuous exposure to increasing concentrations of cisplatin. The A549/DDP cell line exhibits resistance to cisplatin-induced cell death and serves as a valuable model for studying mechanisms of drug resistance in lung cancer.

The development of drug resistance in cancer cells is a major challenge in cancer treatment, as it limits the effectiveness of chemotherapy and contributes to treatment failure. A549/DDP cells have been extensively studied to understand the molecular mechanisms underlying cisplatin resistance, including alterations in drug uptake and efflux, changes in DNA repair mechanisms, and activation of anti-apoptotic pathways.

Research using the A549/DDP cell line has provided important insights into the complex interplay of molecular pathways that contribute to drug resistance in lung cancer. By elucidating these mechanisms, researchers can identify potential therapeutic targets to overcome drug resistance and develop novel treatment strategies for patients with lung cancer.